StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Basaglar (insulin glargine) by Quarter

Basaglar (insulin glargine) — Worldwide revenue YoY (%) [legacy] (%)

QuarterlyAnnual

Eli Lilly Basaglar (insulin glargine): -10.0% in Q3 2024, down 3.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q3 2024
-10.0%
Period ended Sep 30, 2024
Change on a year earlier
-3.0 pts
-7.0% in Q3 2023
History
23 quarters
Since Q1 2018
Sources
23
Documents cited below

Where the Q3 2024 figure comes from

“|| Basaglar ® (3) | 85.5 | 76.2 | 161.6 | 179.6 | (10)”

Source: Form 10-Q FY2024Q3 (filed 2024-10-30) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBasaglar (insulin glargine) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q3 2024Sep 30, 2024-10.0%-3.0 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q2 2024Jun 30, 202417.0%+28.0 ptsForm 10-Q FY2024Q2 (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024-25.0%-34.0 ptsForm 10-Q FY2024Q1 (filed 2024-04-30) ↗
Q3 2023Sep 30, 2023-7.0%-7.0 ptsForm 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q2 2023Jun 30, 2023-11.0%+6.0 ptsForm 10-Q FY2023Q2 (filed 2023-08-08) ↗
Q1 2023Mar 31, 20239.0%+31.0 ptsForm 10-Q FY2023Q1 (filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-17.0%-3.0 ptsEarnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 20220.0%+22.0 ptsEarnings Release (Form 8-K FY2022Q3 EX-99.1) (filed 2022-11-01) ↗
Q2 2022Jun 30, 2022-17.0%+10.0 ptsForm 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q1 2022Mar 31, 2022-22.0%-3.0 ptsForm 10-Q FY2022Q1 (filed 2022-04-29) ↗
Q4 2021Dec 31, 2021-14.0%-6.0 ptsEarnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-22.0%-16.0 ptsForm 10-Q FY2021Q3 (filed 2021-10-27) ↗
Q2 2021Jun 30, 2021-27.0%–Form 10-Q FY2021Q2 (filed 2021-08-03) ↗
Q1 2021Mar 31, 2021-19.0%-40.0 ptsForm 10-Q FY2021Q1 (filed 2021-04-30) ↗
Q4 2020Dec 31, 2020-8.0%–Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗
Q3 2020Sep 30, 2020-6.0%-37.0 ptsForm 10-Q FY2020Q3 (filed 2020-10-28) ↗

Cite this data

StockData. (2026). Eli Lilly Basaglar (insulin glargine) (%), quarterly Q1 2018–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-basaglar-yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.